Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Summary

The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.

Timeline

Start

2023-03-01

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications